The researchers described the unprecedented speed of the oversight steps as being "through alternative procedures." In month ...

In both children and adults, the drug allows for decreasing glucocorticoid dosing to physiological levels while still ...

Close collaboration between researchers and clinicians at Mayo is what makes the steps of translation — from discovery to the ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed ...

Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three ...

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First ...

Herantis Pharma Plc - Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson's disease HER-096 is a first-in-class agent in development for ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

The Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain.